Pluri Inc. announced that its CDMO division (PluriCDMO?) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. PluriCDMO? will support Remedy Cell?s production team in the manufacturing of a clinical-grade Working Cell Bank (WCB) and GMP batches of Remedy Cell?s drug candidate RC-0315, derived from mesenchymal stem cells, towards the launch of their Phase Ib clinical trial for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a lethal, complex, progressive interstitial lung disorder with a median survival of 3.8 years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.357 USD | +9.33% | +2.04% | +15.55% |
Apr. 08 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
Apr. 08 | Sector Update: Health Care | MT |
1st Jan change | Capi. | |
---|---|---|
+15.55% | 27.91M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- PLUR Stock
- News Pluri Inc.
- Pluri Selected as Cdmo by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing